How are cancer and inflammation interrelated mechanistically and clinically? Though extensive literature exists on the topic "Cancer and Inflammation," there are relatively few texts that have truly integrated the two in spite of the many common mechanisms shared by their processes. Certainly, areas such as cytokines, growth factors, proliferation, signal transduction and angiogenesis, for example, are found in both. Yet, the dynamics of how these common mechanisms are maybe interrelated in the pathologies of the two is not widely covered. Such coverage, as presented in this volume, may help further understanding and bring new approaches to therapeutics.

The first section of the book discusses inflammatory mechanisms, studied in cellular and animal studies. The second part concentrates on clinical studies with antiinflammatory drugs in cancer treatment. The volume is written for biomedical researchers in the health care industry and in academia who are working in these areas.

Contents. List of Contributors. Preface. T.J. Mitchell and T.J. Williams: The role of eotaxin and related CC-chemokines in asthma and allergy. Roger J. Davis: Signal transduction by the JNK group of MAP kinases. Marie Chabot-Fletcher: TNF and IL-1 signaling to NF-kB. Anthony M. Manning: Small molecule regulators of AP-1 and NF-kB. Robert T. Abraham: Mammalian target of rapamycin: Immunosuppressive drugs offer new insights into cell growth regulation. Catherine A. Burton, John Boylan, Candy Robinson, Janet Kerr and Pamela Benfield: Constitutive expression of a tumor suppressor leads to tumor regression in a xenograft model. Steven D. Shapiro: Macrophage metalloproteinases in destructive inflammatory diseases. Nancy H. Ruddle: Lymphotoxin in inflammation and lymphoid organ development: Variations on a theme. Steven L. Kunkel, Sem H. Phan, Nicholas W. Lukacs, Cory Hogaboam and Stephen W. Chensue: Chemokine/cytokine biology during the evolution of fibrotic disease. Long Gu, Susan C. Tseng and Barrett J. Rollins: The role of MCP-1 in disease. Lisa A. Beck, Cristiana Stellato, Syed Shahabuddin, Renate Nickel and Robert P. Schleimer: The role of chemokines in allergic diseases of the airways. James Winkler and Ken Tramposch (coordicators): Ninth International Conference of the Inflammation Research Association, November 1-5, 1998: Summaries of workshops and poster discussions. William Williams and Elizabeth Arner (chair persons): Targets in rheumatoid and osteoarthritis. Lawrence Wennogle and Nancy Cusack (chair persons): Signal transduction and regulation of gene expression. James Burke and Floyd Chilton (chair persons): Mediators in inflammation and their enzymes. Denis Schrier and Fandrew Issekutz (chair persons): Cell adhesion molecules and leukocyte trafficking. Robert M. Strieter and David Underwood (chair persons): Pulmonary inflammation, fibrosis, and disease. W. Hunter and E. Turley (chair persons): Angiogenesis, wound repair and skin inflammation. Index.

Purpose of In vivo Models of Inflammation is to provide the biomedical researcher in both the pharmaceutical industry and academia with a description of the state of the art animal model systems used to emulate diseases with components of inflammation. The aim of this second edition is to act as a complement to the first by describing and updating the standard models that are most utilized for specific disease areas. In addition, this 2nd edition includes new models exploring emerging areas of inflammation research.

It provides detailed descriptions of the methodologies and uses of the most significant models. This includes current information regarding agents that demonstrate efficacy, those that do not and those that can be used as standard controls. The focus remains on those models that serve as pre-clinical correlates to human disease as well as those that represent components of the inflammatory response.

New approaches to the development of future models in selected therapeutic areas have been highlighted. The focus on novel technologies that are vital for innovative in vivo research has also been expanded to include chapters on the use of transgenic and gene transfer technologies, nanotechnology, and stem cells.

The book provides the scientist with an up-to-date reference manual for selecting the best animal model for their specific question. Chapters describing current regulations in the United States, United Kingdom, and Japan are also included.

How are cancer and inflammation interrelated mechanistically and clinically? Though extensive literature exists on the topic "Cancer and Inflammation," there are relatively few texts that have truly integrated the two in spite of the many common mechanisms shared by their processes. Certainly, areas such as cytokines, growth factors, proliferation, signal transduction and angiogenesis, for example, are found in both. Yet, the dynamics of how these common mechanisms are maybe interrelated in the pathologies of the two is not widely covered. Such coverage, as presented in this volume, may help further understanding and bring new approaches to therapeutics.

The first section of the book discusses inflammatory mechanisms, studied in cellular and animal studies. The second part concentrates on clinical studies with antiinflammatory drugs in cancer treatment. The volume is written for biomedical researchers in the health care industry and in academia who are working in these areas.

The Seventh International Conference of the Inflammation Research Association, entitled "Inflammation, Mechanisms and Therapeutics" was held on September 25-29,1994 in White Haven, Pennsylvania. The major focus of this series of conferences is the multidisciplinary investigation of inflammation and the discovery of novel therapeutic approaches to inflammatory diseases. It was therefore particularly gratifying that the list of attendees included scientists of diverse backgrounds - preclinical biology, synthetic and theoretical chemistry, biotechnology and clinical research. The Conference was characterized by a very high degree of participation in the scientific debate by attendees, a large proportion of whom presented at poster sessions, poster discussions and workshops, and by the many opportunities for informal discussion provided by the organizers. This volume captures much of the excitement and enthusiasm of the Conference and should be a valuable resource for scientists in the field. Niall S. Doherty Barry M. Weichman Douglas W. Morgan Lisa A. Marshall IX Acknowledgments The manuscripts contained in this volume are based on material presented at the Seventh International Conference of the Inflammation Research Association held in White Haven, Pennsylvania, on September 25-29,1994. We would like to thank the speakers and session chairpersons for their contributions to the Conference and these Proceedings. The following individuals played indispensable roles in the organization and running of the Conference and are responsible for making it such a success: PLANNING SCHOLARSHIP Niall S. Doherty Janet Kerr, Chairperson Barry M. Weichman Richard Carlson Douglas Morgan Richard Harris Loran Killar D.

In Vivo Models of Inflammation (Volume 1 and Volume 2) provides the biomedical researcher in both the pharmaceutical industry and academia with a description of the state of the art animal model systems used to emulate diseases with components of inflammation. This second edition acts as a complement to the first edition by describing and updating the standard models that are most utilized for specific disease areas. In addition, new models are included exploring emerging areas of inflammation research. The format is designed with the laboratory in mind: Both volumes provide detailed descriptions of the methodologies and uses of the most significant models. This includes current information regarding agents that demonstrate efficacy, those that do not and those that can be used as standard controls. The focus remains on those models that serve as pre-clinical correlates to human disease as well as those that represent components of the inflammatory response. Pioneering ideas and provocative comments about future directions are meant to challenge the status quo and stimulate new thinking. Therefore, new approaches to the development of future models in selected therapeutic areas have been highlighted. The focus on novel technologies that are vital for innovative in vivo research has been expanded to include chapters on the use of transgenic and gene transfer technologies, nanotechnology, and stem cells. This up-to-date reference manual helps to select the best animal model for a specific question. At the same time, this set of books continues to acknowledge the solemn responsibility in vivo research carries with it and extends the coverage of animal respect and welfare when used in experimental settings. Chapters describing current regulations in the United States, United Kingdom, and Japan address these concerns. Thus, the ultimate aim of this set of books is to provide current best practices for obtaining the maximum informat

In November 1998 many of the key leaders of new drug discovery for inflammatory diseases gathered at Hershey, Pennsylvania for the 9th International Conference of the Inflammation Research Association. The Conference was held over a five day period and provided a stimulating environment for the open exchange of important advances in basic inflammation research as well as new drug discovery and development. This book encompasses some of the highlights of several presentations made at the Conference. It contains some of the latest and important developments in the field of inflammation research. Topics include the status of eotaxin and chemokines in asthma and allergy, signal transduction and regulation of diverse mediators such as the JNK group of MAP kinases, TNF and IL-1 signaling of NF-kB as well as regulators of AP-1, macrophage metalloproteinases, lymphotoxin and further insights into the role of MCP-1 in disease. Also discussed are drug targets in rheumatoid and osteoarthritis, fibrotic diseases,...

In Vivo Models of Inflammation (Vol. 1 and Vol. 2) provides biomedical researchers in both the pharmaceutical industry and academia with a description of the state-of-the-art animal model systems used to emulate diseases with components of inflammation. This second edition acts as a complement to the first, describing and updating the standard models that are most utilized for specific disease areas. New models are included exploring emerging areas of inflammation research.